Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISINE vs TYZINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.
Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.
Relief of ocular redness due to minor irritations,Off-label: symptomatic treatment of allergic conjunctivitis
Symptomatic relief of nasal congestion due to common cold, sinusitis, or allergic rhinitis,Off-label: relief of eustachian tube congestion
1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.
Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.
Approximately 1-2 hours for ocular absorption; systemic half-life not clinically relevant due to low systemic absorption
Terminal elimination half-life is approximately 3-4 hours; clinically, this supports dosing every 8-12 hours.
Not systemically absorbed; no significant metabolism occurs in the eye.
Primarily hepatic metabolism via oxidation and reduction pathways; no specific CYP enzymes identified.
Primarily renal as unchanged drug and metabolites; minor biliary/fecal elimination (<10%)
Renal elimination of unchanged drug and metabolites accounts for approximately 50% of the dose; fecal elimination is minimal.
Approximately 80% bound to plasma proteins, primarily albumin
Approximately 50% bound to plasma proteins, primarily albumin.
Not clinically significant for topical ophthalmic use; systemic Vd estimated at 0.5-1 L/kg based on IV data
Approximately 1.5 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ocular: negligible systemic bioavailability (<1% from topical dose); oral not applicable
Intranasal: approximately 100% (local effect); systemic bioavailability is low due to local vasoconstriction limiting absorption.
No dose adjustment required; systemic absorption is minimal.
No dose adjustment required.
No dose adjustment required; systemic absorption is minimal.
No dose adjustment required.
Children 6 years and older: 1 drop in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily. Safety and efficacy in children under 6 years not established.
Children 6-12 years: Instill 1-2 drops of 0.05% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day. For children under 6: Not recommended.
No specific dose adjustment, but use with caution due to increased risk of systemic effects (e.g., hypertension, cardiac arrhythmias) and potential for angle-closure glaucoma.
Use with caution due to increased sensitivity and risk of adverse effects; consider lower concentration (0.05%) and limit duration of use to 3-5 days.
None
None
Do not use in patients with narrow-angle glaucoma; overuse may cause rebound hyperemia; avoid in children under 6 years; discontinue if eye pain or vision changes occur.
Rebound congestion (rhinitis medicamentosa) with prolonged use,Potential for systemic effects with excessive use (hypertension, palpitations),Use caution in cardiovascular disease, hypertension, hyperthyroidism, diabetes, and glaucoma
Hypersensitivity to tetrahydrozoline or any component; narrow-angle glaucoma; concurrent use with MAO inhibitors
Known hypersensitivity to tetrahydrozoline,Angle-closure glaucoma,Concurrent use with MAO inhibitors or within 14 days of discontinuation
No known food interactions. Avoid alcohol as it may exacerbate eye redness or irritation.
None known. No specific dietary restrictions.
No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. Second and third trimesters: no specific risks identified. However, avoid prolonged use due to potential vasoconstrictive effects.
Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no known teratogenicity but risk of maternal hypertension and reduced placental perfusion.
Negligible systemic absorption with topical ocular use; M/P ratio not determined. Excretion into breast milk unlikely. Considered compatible with breastfeeding; use caution with excessive or prolonged use.
No data on excretion in breast milk; M/P ratio unknown. Consider risk of infant systemic effects (tachycardia, hypertension) given vasoconstrictor properties. Only use if clearly indicated and monitor infant for adverse effects.
No dose adjustments necessary for pregnancy as systemic absorption is negligible. Standard dosing (1-2 drops every 8-12 hours) applies. Avoid overuse due to potential for rebound congestion or systemic effects.
No specific pharmacokinetic studies in pregnancy. Use lowest effective dose for shortest duration. Avoid systemic absorption (e.g., nasal spray for local effect). No dose adjustment recommended based on available evidence.
Visine (tetrahydrozoline) is a topical ocular decongestant; prolonged use (>72 hours) can cause rebound hyperemia and conjunctivitis medicamentosa. Avoid in patients with narrow-angle glaucoma, cardiovascular disease, or hypertension. Do not use in children under 2 years without medical advice.
Tyzine (tetrahydrozoline) is an imidazoline derivative with alpha-adrenergic agonist activity. It causes vasoconstriction of conjunctival blood vessels but may produce rebound hyperemia, mydriasis, and systemic effects if overused. Avoid in narrow-angle glaucoma. Use with caution in patients with hypertension, cardiovascular disease, hyperthyroidism, or diabetes. Do not use longer than 72 hours to prevent rebound congestion. Contact lens wearers should remove lenses before instillation. Do not use in patients with MAOI therapy or within 14 days of discontinuation.
Do not use Visine for more than 3 days to avoid rebound redness.,Remove contact lenses before instilling drops and wait at least 15 minutes before reinserting.,Do not share the bottle to prevent infection.,Avoid touching the dropper tip to any surface or the eye.,If eye pain, vision changes, or persistent redness occur, discontinue use and consult a doctor.
Do not use more than the recommended dose or for longer than 3 days.,Remove contact lenses before using drops and wait at least 15 minutes before reinserting.,Avoid touching the dropper tip to any surface to prevent contamination.,Do not share the medication with others.,If you experience eye pain, vision changes, or redness lasting >72 hours, stop use and consult a doctor.,Do not use if pregnant or breastfeeding without medical advice.,Keep out of reach of children; accidental ingestion may cause serious side effects.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about VISINE vs TYZINE, answered by our medical review team.
VISINE is a Ophthalmic Decongestant that works by Tetrahydrozoline is a sympathomimetic amine that acts as an alpha-1 adrenergic receptor agonist, causing vasoconstriction of conjunctival blood vessels, thereby reducing redness and edema.. TYZINE is a Ophthalmic Decongestant that works by Imidazoline sympathomimetic amine that stimulates alpha-2 adrenergic receptors in the nasal vasculature, producing vasoconstriction and reducing nasal congestion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between VISINE and TYZINE depend on the specific clinical indication. These are both Ophthalmic Decongestant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of VISINE is: 1-2 drops in affected eye(s) every 6-8 hours as needed, not to exceed 4 times daily.. The standard adult dose of TYZINE is: Instill 1-2 drops of 0.1% solution into each nostril every 4-6 hours as needed; not to exceed 4 doses per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between VISINE and TYZINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. VISINE is classified as Category C. No evidence of teratogenicity in animal studies. In humans, limited data; topical ocular use results in negligible systemic absorption. First trimester: theoretical risk minimal. S. TYZINE is classified as Category C. Limited human data; animal studies not conducted. Inadequate evidence for first trimester risk. Avoid during entire pregnancy unless clearly needed. Second and third trimester: no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.